Double‐blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics

Publisher Website
Google Scholar
Abstract
Chronic schizophrenics (50) were randomly assigned to a 16-wk treatment either with fluspirilene or with fluphenazine decanoate. The antipsychotic action and the side effects of the 2 neuroleptics were compared. Fluphenazine decanoate caused more side effects and the difference between the 2 groups was statistically significant in the items tremor, severe extrapyramidal effects and parkinsonism. More patients in the fluspirilene group (9 patients) compared with only 3 in the fluphenazine decanoate group remained free of side effects during the whole trial. Judged from the BPRS [Brief Psychiatric Rating Scale] fluspirilene proved an equally potent neuroleptic with fluphenazine decanoate, although statistically significant improvement was obtained in more items of the scale in the fluspirilene group. The improvement in the NOSIE-30 [Nurses'' Observation Scale for Inpatient Evaluation] was much more clear in the fluspirilene group.